FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc
- Johnson & Johnson
- LG Life Sciences Ltd.
- Novartis
- Pfizer Inc.
Erythropoietin (EPO) Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global erythropoietin (epo) market.
This report focuses on the erythropoietin (epo) market which is experiencing strong growth. The report gives a guide to the erythropoietin (epo) market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.
Where is the largest and fastest growing market for erythropoietin (epo)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Erythropoietin (EPO) market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider erythropoietin (epo) market, and compares it with other markets.
Amgen Inc.; Johnson & Johnson; Roche Group; Pfizer Inc.; Novartis
Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Five years historic and ten years forecast.
Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Country and regional historic and forecast data, market share of competitors, market segments.
Data and analysis throughout the report is sourced using end notes.
This product will be delivered within 1-3 business days.
This report focuses on the erythropoietin (epo) market which is experiencing strong growth. The report gives a guide to the erythropoietin (epo) market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for erythropoietin (epo)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Erythropoietin (EPO) market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider erythropoietin (epo) market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The erythropoietin (epo) market section of the report gives context. It compares the erythropoietin (epo) market with other segments of the erythropoietin (epo) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, erythropoietin (epo) indicators comparison.
Scope
Markets Covered:
- By Product: Epoetin-alfa; Epoetin-beta; Darbepoetin-alfa; Others
- By Application: Cancer; Hematology; Renal diseases; Neurology; Others
- By Drug Class: Biologis; Biosimilar
Companies Mentioned:
Amgen Inc.; Johnson & Johnson; Roche Group; Pfizer Inc.; Novartis
Countries:
Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions:
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data segmentations:
Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing:
Data and analysis throughout the report is sourced using end notes.
This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Erythropoietin (EPO) Market
What is the estimated value of the Global Erythropoietin (EPO) Market?
What is the growth rate of the Global Erythropoietin (EPO) Market?
What is the forecasted size of the Global Erythropoietin (EPO) Market?
Who are the key companies in the Global Erythropoietin (EPO) Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc
- Johnson & Johnson
- LG Life Sciences Ltd.
- Novartis
- Pfizer Inc.
1. Executive Summary2. Erythropoietin (EPO) Market Characteristics3. Erythropoietin (EPO) Market Trends and Strategies4. Impact Of COVID-19 On Erythropoietin (EPO)28. Erythropoietin (EPO) Pipeline Analysis29. Key Mergers and Acquisitions in the Erythropoietin (EPO) Market30. Erythropoietin (EPO) Market Future Outlook and Potential Analysis
5. Erythropoietin (EPO) Market Size and Growth
6. Erythropoietin (EPO) Market Segmentation
7. Erythropoietin (EPO) Market Regional and Country Analysis
8. Asia-Pacific Erythropoietin (EPO) Market
9. China Erythropoietin (EPO) Market
10. India Erythropoietin (EPO) Market
11. Japan Erythropoietin (EPO) Market
12. Australia Erythropoietin (EPO) Market
13. Indonesia Erythropoietin (EPO) Market
14. South Korea Erythropoietin (EPO) Market
15. Western Europe Erythropoietin (EPO) Market
16. UK Erythropoietin (EPO) Market
17. Germany Erythropoietin (EPO) Market
18. France Erythropoietin (EPO) Market
19. Eastern Europe Erythropoietin (EPO) Market
20. Russia Erythropoietin (EPO) Market
21. North America Erythropoietin (EPO) Market
22. USA Erythropoietin (EPO) Market
23. South America Erythropoietin (EPO) Market
24. Brazil Erythropoietin (EPO) Market
25. Middle East Erythropoietin (EPO) Market
26. Africa Erythropoietin (EPO) Market
27. Erythropoietin (EPO) Market Competitive Landscape and Company Profiles
31. Appendix
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc
- Johnson & Johnson
- LG Life Sciences Ltd.
- Novartis
- Pfizer Inc.
Major players in the erythropoietin (EPO) market are Amgen Inc., Johnson & Johnson, Roche Group, Pfizer Inc., Novartis, Celltrion Inc, and LG Life Sciences Ltd.
The global erythropoietin (EPO) market is expected to grow from $0.96 billion in 2020 to $1.1 billion in 2021 at a compound annual growth rate (CAGR) of 14.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $3.11 billion in 2025 at a CAGR of 30%.
The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars. Erythropoietin (EPO) is a hormone produced by kidneys and plays a vital role in the production of red blood cells, which carry oxygen from the lungs to the rest of the body. Lack of sufficient erythropoietin results in low red blood cells, which may lead to anaemia. The erythropoietin (EPO) drugs are used for treatment for anaemia, kidney disorders, cancer, and other conditions.
The erythropoietin market covered in this report is segmented by product into epoetin-alfa, epoetin-beta, darbepoetin-alfa, others and by application into cancer, hematology, renal diseases, neurology, others.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Stringent regulations imposed on the production and sales of erythropoietin drugs are predicted to hinder the growth of the erythropoietin market over the forecast period. For instance, in European Community (EC), technologically advanced medicinal products manufactured using a biotechnological process such as recombinant DNA technology should comply with marketing authorization (MA) under provisions of Regulation (EC) No. 726/04 issued by EC. The regulatory policy for biosimilars is complex and in Europe is mainly governed by guidelines issued by the European Medicines Agency (EMEA). In addition to this, recombinant human erythropoietin (rHuEPO) must fulfill additional product-class specific guidelines apart from regulations on quality, clinical, and non-clinical issues developed by the EMEA.
In August 2018, STADA Arzneimittel AG, a Germany-based pharmaceutical company, acquired majority stakes (51.34%) in Bioceuticals Arzneimittel AG for an undisclosed amount. The acquisition is expected to expand STADA Arzneimittel AG‘s presence in the biosimilar sector. Bioceuticals Arzneimittel AG licenses marketing rights to epoetin zeta and epoetin biosimilar to STADA Arzneimittel AG. Bioceuticals Arzneimittel AG is a Germany-based company engaged in manufacturing and marketing active pharmaceutical ingredients including erythropoietin biosimilars.
The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the approaching years. According to the Brazilian Journal of Nephrology’s statistics published in February 2019, kidney disease is a global public healthcare problem affecting over 750 million people across the globe. In addition to this, according to the Centers for Disease Control and Prevention’s report published on chronic kidney disease in the United States, in 2019, 15% of the adults in the USA, or 37 million people are estimated to have chronic kidney disease (CKD). CKD is more common in people aged 65 or older (38%) than in people aged 45-64 years (13%) and 18-44 years (7%). Chronic kidney diseases lead to an anaemic condition which in turn increases the demand for erythropoietin to curb the condition, thereby driving the revenues for the market.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The global erythropoietin (EPO) market is expected to grow from $0.96 billion in 2020 to $1.1 billion in 2021 at a compound annual growth rate (CAGR) of 14.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $3.11 billion in 2025 at a CAGR of 30%.
The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars. Erythropoietin (EPO) is a hormone produced by kidneys and plays a vital role in the production of red blood cells, which carry oxygen from the lungs to the rest of the body. Lack of sufficient erythropoietin results in low red blood cells, which may lead to anaemia. The erythropoietin (EPO) drugs are used for treatment for anaemia, kidney disorders, cancer, and other conditions.
The erythropoietin market covered in this report is segmented by product into epoetin-alfa, epoetin-beta, darbepoetin-alfa, others and by application into cancer, hematology, renal diseases, neurology, others.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Stringent regulations imposed on the production and sales of erythropoietin drugs are predicted to hinder the growth of the erythropoietin market over the forecast period. For instance, in European Community (EC), technologically advanced medicinal products manufactured using a biotechnological process such as recombinant DNA technology should comply with marketing authorization (MA) under provisions of Regulation (EC) No. 726/04 issued by EC. The regulatory policy for biosimilars is complex and in Europe is mainly governed by guidelines issued by the European Medicines Agency (EMEA). In addition to this, recombinant human erythropoietin (rHuEPO) must fulfill additional product-class specific guidelines apart from regulations on quality, clinical, and non-clinical issues developed by the EMEA.
In August 2018, STADA Arzneimittel AG, a Germany-based pharmaceutical company, acquired majority stakes (51.34%) in Bioceuticals Arzneimittel AG for an undisclosed amount. The acquisition is expected to expand STADA Arzneimittel AG‘s presence in the biosimilar sector. Bioceuticals Arzneimittel AG licenses marketing rights to epoetin zeta and epoetin biosimilar to STADA Arzneimittel AG. Bioceuticals Arzneimittel AG is a Germany-based company engaged in manufacturing and marketing active pharmaceutical ingredients including erythropoietin biosimilars.
The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the approaching years. According to the Brazilian Journal of Nephrology’s statistics published in February 2019, kidney disease is a global public healthcare problem affecting over 750 million people across the globe. In addition to this, according to the Centers for Disease Control and Prevention’s report published on chronic kidney disease in the United States, in 2019, 15% of the adults in the USA, or 37 million people are estimated to have chronic kidney disease (CKD). CKD is more common in people aged 65 or older (38%) than in people aged 45-64 years (13%) and 18-44 years (7%). Chronic kidney diseases lead to an anaemic condition which in turn increases the demand for erythropoietin to curb the condition, thereby driving the revenues for the market.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Amgen Inc.
- Johnson & Johnson
- Roche Group
- Pfizer Inc.
- Novartis
- Celltrion Inc
- LG Life Sciences Ltd.
Note: Product cover images may vary from those shown
LOADING...